Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the " Real-life " : Result of the French Experience in 72 Adults
NCT01013181 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2009-11-17
Summary
The purpose of this study is to review the charts of the first 100 patients included in the french compassionate program including patients with Immune Thrombopenia receiving romiplostim.
Conditions
- Thrombopenia
Sponsors & Collaborators
- collaborator INDUSTRY
-
Paris 12 Val de Marne University
collaborator OTHER -
Henri Mondor University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-01-31
- Primary Completion
- 2008-07-31
- Completion
- 2009-08-31
More Related Trials
-
Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell
NCT01980030 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
NCT00907478 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT01444417 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
NCT00111475 ·Status: COMPLETED ·Phase: PHASE2
-
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
NCT01143038 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
NCT01071954 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
NCT00515203 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)
NCT02868099 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
NCT02052882 ·Status: COMPLETED ·Phase: PHASE2
-
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
NCT06992128 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)
NCT02868060 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid Tumors
NCT07128576 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Indirect Comparison Between Eltrombopag & Romiplostim
NCT01236014 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
NCT04200456 ·Status: TERMINATED ·Phase: PHASE3
-
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
NCT07063225 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
NCT04638829 ·Status: COMPLETED ·Phase: PHASE4
-
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
NCT00415532 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic Anemia
NCT07345000 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim
NCT01439321 ·Status: COMPLETED
-
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
NCT00117143 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety of Romiplostim (Nplate®) Following UCBT
NCT02046291 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training
NCT02085993 ·Status: COMPLETED
-
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
NCT00508820 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)
NCT00472290 ·Status: COMPLETED ·Phase: NA
-
Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
NCT01443351 ·Status: WITHDRAWN